PD1 peptide plasmid

PD1 peptide plasmid refers to a DNA-based therapeutic platform consisting of a plasmid vector engineered to express a peptide sequence derived from the Programmed Cell Death Protein 1 (PD-1) receptor. This modality functions primarily as a DNA vaccine or a localized gene therapy. Upon administration—typically via intramuscular injection followed by electroporation or direct intratumoral injection—the plasmid transfects host cells, which then synthesize and present the encoded PD-1 peptide. The therapeutic intent is generally twofold: either to serve as an immunogen that stimulates the production of endogenous anti-PD-1 antibodies (a B-cell vaccine approach) or to produce a peptide that directly competes with the PD-1/PD-L1 interaction. By blocking this checkpoint, the therapy aims to restore the activity of exhausted T-cells and enhance the immune system's ability to recognize and eliminate malignant cells. While several variations have been explored in preclinical models for various cancers, this platform remains largely in the experimental and early clinical stages of development.

Other names

PD-1 peptide DNA vaccinePD1 peptide DNA vaccinePD 1 peptide DNA vaccineplasmid-encoded PD-1 peptidePD-1 peptide-based DNA vaccinePD1 peptide-based DNA vaccinePD 1 peptide-based DNA vaccine